Search

Your search keyword '"Weimer, Melissa B."' showing total 198 results
Start Over Author "Weimer, Melissa B."
198 results on '"Weimer, Melissa B."'

8. National HIV and HCV Screening Rates for Hospitalized People Who Use Drugs Are Suboptimal and Heterogeneous across 11 U.S. Hospitals

Author

Westgard, Leo Knudsen, primary, Sato, Taisuke, additional, Bradford, William S, additional, Eaton, Ellen F, additional, Pilcher, Finlay, additional, Hale, Andrew J, additional, Singh, Devika, additional, Martin, Marlene, additional, Appa, Ayesha A, additional, Meyer, Jaimie P, additional, Weimer, Melissa B, additional, Barakat, Lydia A, additional, Felsen, Uriel R, additional, Akiyama, Matthew J, additional, Ridgway, Jessica P, additional, Grussing, Emily D, additional, Thakarar, Kinna, additional, White, Amy, additional, Mutelayi, John, additional, Krsak, Martin, additional, Montague, Brian T, additional, Nijhawan, Ank, additional, Balakrishnan, Harini, additional, Marks, Laura R, additional, and Wurcel, Alysse G, additional

Published
2024
Full Text
View/download PDF

14. The American Society of Addiction Medicine Clinical Practice Guideline Development Methodology.

Author

Weimer, Melissa B., Devoto, Amanda, Kansagara, Devan, Safarian, Taleen, Brunner, Emily, Stock, Audra, Rastegar, Darius A., Nelson, Lewis S., Tirado, Carlos F., Korthuis, P. Todd, and Boyle, Maureen P.

Abstract

The American Society of Addiction Medicine (ASAM) has published clinical practice guidelines (CPGs) since 2015. As ASAM's CPG work continues to develop, it maintains an organizational priority to establish rigorous standards for the trustworthy production of these important documents. In keeping with ASAM's mission to define and promote evidence-based best practices in addiction prevention, treatment, and recovery, ASAM has rigorously updated its CPG methodology to be in line with evolving international standards. The CPG Methodology and Oversight Subcommittee was formed to establish and publish a methodology for the development of ASAM CPGs and to develop an ASAM CPG strategic plan. This article provides a focused overview of the ASAM CPG methodology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine

Author

Neale, Kyle J., primary, Weimer, Melissa B., additional, Davis, Mellar P., additional, Jones, Katie Fitzgerald, additional, Kullgren, Justin G., additional, Kale, Sachin S., additional, Childers, Julie, additional, Broglio, Kathleen, additional, Merlin, Jessica S., additional, Peck, Sarah, additional, Francis, Sheria Y., additional, Bango, Jacqueline, additional, Jones, Christopher A., additional, Sager, Zachary, additional, and Ho, J. Janet, additional

Published
2023
Full Text
View/download PDF

25. ASAMClinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids.

Author

Weimer, Melissa B., Herring, Andrew A., Kawasaki, Sarah S., Meyer, Marjorie, Kleykamp, Bethea A., and Ramsey, Kelly S.

Abstract

Treatment of opioid use disorder (OUD) with buprenorphine has evolved considerably in the last decade as the scale of the OUD epidemic has increased along with the emergence of high-potency synthetic opioids (HPSOs) and stimulants in the drug supply. These changes have outpaced the development of prospective research, so a clinical consideration document based on expert consensus is needed to address pressing clinical questions. This clinical considerations document is based on a narrative literature review and expert consensus and will specifically address considerations for changes to the clinical practice of treatment of OUD with buprenorphine for individuals using HPSO. An expert panel developed 6 key questions addressing buprenorphine initiation, stabilization, and long-term treatment for individuals with OUD exposed to HPSO in various treatment settings. Broadly, the clinical considerations suggest that individualized strategies for buprenorphine initiation may be needed. The experience of opioid withdrawal negatively impacts the success of buprenorphine treatment, and attention to its management before and during buprenorphine initiation should be proactively addressed. Buprenorphine dose and dosing frequency should be individualized based on patients' treatment needs, the possibility of novel components in the drug supply should be considered during OUD treatment, and all forms of opioid agonist treatment should be offered and considered for patients. Together, these clinical considerations attempt to be responsive to the challenges and opportunities experienced by frontline clinicians using buprenorphine for the treatment of OUD in patients using HPSOs and highlight areas where prospective research is urgently needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines

Author

Calcaterra, Susan L., primary, Bottner, Richard, additional, Martin, Marlene, additional, Englander, Honora, additional, Weinstein, Zoe M., additional, Weimer, Melissa B., additional, Lambert, Eugene, additional, Ronan, Matthew V., additional, Huerta, Sergio, additional, Zaman, Tauheed, additional, Ullal, Monish, additional, Peterkin, Alyssa F., additional, Torres‐Lockhart, Kristine, additional, Buresh, Megan, additional, O'Brien, Meghan T., additional, Snyder, Hannah, additional, and Herzig, Shoshana J., additional

Published
2022
Full Text
View/download PDF

35. Perioperative Buprenorphine Management

Author

Hickey, Thomas, primary, Abelleira, Audrey, additional, Acampora, Gregory, additional, Becker, William C., additional, Falker, Caroline G., additional, Nazario, Mitchell, additional, and Weimer, Melissa B., additional

Published
2022
Full Text
View/download PDF

40. Management of Infective Endocarditis in People Who Inject Drugs: A Scientific Statement From the American Heart Association.

Author

Baddour, Larry M., Weimer, Melissa B., Wurcel, Alysse G., McElhinney, Doff B., Marks, Laura R., Fanucchi, Laura C., Esquer Garrigos, Zerelda, Pettersson, Gosta B., and DeSimone, Daniel C.

Abstract

Background: The American Heart Association has sponsored both guidelines and scientific statements that address the diagnosis, management, and prevention of infective endocarditis. As a result of the unprecedented and increasing incidence of infective endocarditis cases among people who inject drugs, the American Heart Association sponsored this original scientific statement. It provides a more in-depth focus on the management of infective endocarditis among this unique population than what has been provided in prior American Heart Association infective endocarditis–related documents. Methods: A writing group was named and consisted of recognized experts in the fields of infectious diseases, cardiology, addiction medicine, and cardiovascular surgery in October 2021. A literature search was conducted in Embase on November 19, 2021, and multiple terms were used, with 1345 English-language articles identified after removal of duplicates. Conclusions: Management of infective endocarditis in people who inject drugs is complex and requires a unique approach in all aspects of care. Clinicians must appreciate that it requires involvement of a variety of specialists and that consultation by addiction-trained clinicians is as important as that of more traditional members of the endocarditis team to improve infective endocarditis outcomes. Preventive measures are critical in people who inject drugs and are cured of an initial bout of infective endocarditis because they remain at extremely high risk for subsequent bouts of infective endocarditis, regardless of whether injection drug use is continued. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. SOAPs and SUDs

Author

Chan, Carolyn A., primary, Tetrault, Jeanette M., additional, Fiellin, David A., additional, and Weimer, Melissa B., additional

Published
2021
Full Text
View/download PDF

47. Colaboradores

Author

Akhtar, Shamsuddin, Bose, Ruma, Charchaflieh, Jean Gabriel, Chaudhary, Connie W., Choudhury, Nadim, Conte, Antonio Hernandez, Coppes, Oscar, Daxon, Benjamin T., Deshpande, Ranjit, Dillman, Dawn, Diu, Michelle W., Fontes, Manuel, Freed, Julie K., Grecu, Loreta, Guevara, Lindsay R. Hunter, Heerdt, Paul M., Hickey, Thomas R., Hines, Roberta L., Holt, Natalie F., Jones, Stephanie B., Kurup, Viji, Maerz, Linda L., Mahmood, Feroze, McSwain, Julie R., Meng, Marie-Louise, Merritt, William T., Montealegre-Gallegos, Mario, Moon, Tiffany Sun, Oprea, Adriana D., Pagel, Paul S., Pasternak, Jeffrey J., Popescu, Wanda, Pustavoitau, Aliaksei, Rana, Maunak, Rosenbaum, Stanley H., Schonberger, Robert B., Selzer, Angela, Sharkey, Aidan, Simmons, Flora, Smiley, Richard, Steppan, Jochen, Szabo, Christopher, Tantawy, Hossam, Tao, Jing, Tawil, Justin, Wadia, Rajeev S., Walker, Kathryn K., Watson, Kelley Teed, Weimer, Melissa B., and Zuo, Leila

Published
2023
Full Text
View/download PDF

48. Cardiac surgeons’ practices and attitudes toward addiction care for patients with substance use disorders

Author

Nguemeni Tiako, Max Jordan, Mszar, Reed, Brooks, Cornell, Bin Mahmood, Syed Usman, Mori, Makoto, Vallabhajosyula, Prashanth, Geirsson, Arnar, and Weimer, Melissa B.

Abstract

AbstractIntroductionRates of injection-drug use associated infective endocarditis (IDU-IE) are rising, and most patients with IDU-IE do not receive addiction care during hospitalization. We sought to characterize cardiac surgeons’ practices and attitudes toward patients with IDU-IE due to their integral role treating them.MethodsThis is a survey of 201 cardiac surgeons in the U.S who were asked about the addiction care they engage for patients with IDU-IE along with questions pertaining to stigma against people who use drugs (PWUD). Descriptive statistics and multivariable logistic regression were used to identify patterns in surgeons’ practices and determine associations between attitudes toward substance use disorder (SUD) and beliefs about medications for opioid use disorder (MOUD).ResultsA minority of surgeons have access to specialty addiction services (35%) in their hospital, but when available 93% consult them for patients with IDU-IE. A quarter of surgeons reported thinking that SUD is a choice and do not believe MOUD have a role in reducing IDU-IE recurrence. Conversely, 69% of surgeons agreed with the disease model of addiction and were four times more likely to believe that MOUD has a role in reducing IDU-IE recurrence (aOR 4.09, 95% CI 1.8–9.27, p = 0.001).ConclusionAccess to addiction specialists is limited in most hospital settings, but when available, most surgeons report consulting them and supporting MOUD. However, a significant proportion of surgeons hold non-evidence-based attitudes toward SUD and PWUD. This suggests that lack of education and stigma may affect the care of patients with IDU-IE, highlighting the need for education about, and destigmatization of addiction within health systems.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results